Article
Eli Lilly said it has withdrawn its new drug application for duloxetine hydrochloride for the treatment of stress urinary incontinence.
Pivotal data for lumasiran in PH1 published in NEJM
Nedosiran explored in primary hyperoxaluria type 3
Enrollment completed in pivotal trial of nedosiran for hyperoxaluria
FDA approves androgen inhibitor for metastatic PCa
Blood test could guide treatment for kidney cancer
BCG for bladder cancer in short supply
Study findings highlight gender gaps in oncology authorship and citation
ORIC-944 shows promise in combination with AR inhibitors in mCRPC
ASCO 2025: What to watch for in GU oncology
FDA awards Regenerative Medicine Advanced Therapy Designation to CAN-2409 for prostate cancer